ReviewNature reviews. Endocrinology2013
Postmenopausal hormone therapy: risks and benefits.
Review in Nature reviews. Endocrinology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03857893 (Thermal Treatment of Vulvo-vaginal Atrophy), which is not on this map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Thermal Treatment of Vulvo-vaginal Atrophy (VVA) Using Novel Low-energy Dynamic Quadripolar Radio-Frequency (DQRF)
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- Relationship between menopausal hormone therapy and incidence risk of breast cancer: systematic review and meta-analysis.Annals of medicine · 2026Pooled it
- The management of menopause in women with a history of endometriosis: a systematic review.Human reproduction update · 2017Pooled it
- A meta-analysis of reference values of leptin concentration in healthy postmenopausal women.PloS one · 2013Pooled it
- The effect of gabapentin on intensity and duration of hot flashes in postmenopausal women: a randomized controlled trial.Global journal of health science · 2013Trial
- Reduction of glycation stress as a geroscience intervention: protocol for a pilot RCT in postmenopausal women.npj aging · 2026Article
- Cyclodextrin Polymer Complexation Improves the Tolerability of Parenteral Oestradiol.Pharmaceutics · 2026Article
- Impact of Exercise on Perimenopausal Syndrome: A Systematic Review of Randomized Controlled Trials.Cureus · 2025Review
- Age at menopause and multimorbidity in postmenopausal women.Przeglad menopauzalny = Menopause review · 2025Article
- Machine learning-assisted network pharmacology reveals that the Chaihu-Longgu-Muli decoction modulates the inflammatory microenvironment to treat perimenopausal syndrome.Frontiers in molecular biosciences · 2025Article
- Dynamics of serum exosome microRNA profile altered by chemically induced estropause and rescued by estrogen therapy in female mice.GeroScience · 2024Article
- Unsupervised clustering identified clinically relevant metabolic syndrome endotypes in UK and Taiwan Biobanks.iScience · 2024Article
- Association between Female Reproductive Factors and Risk of Dementia.Journal of clinical medicine · 2024Review
- Restoring Wnt signaling in a hormone-simulated postpartum depression model remediated imbalanced neurotransmission and depressive-like behaviors.Molecular medicine (Cambridge, Mass.) · 2023Article
- Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis.Open life sciences · 2023Review
- Sirtuin 3 Plays a Critical Role in the Antidepressant- and Anxiolytic-like Effects of Kaempferol.Antioxidants (Basel, Switzerland) · 2022Article
- Development of di(2-ethylhexyl) phthalate-containing thioglycolic acid immobilized chitosan mucoadhesive gel as an alternative hormone therapy for menopausal syndrome.Bioengineering & translational medicine · 2022Article
- Sex Differences in Cardiovascular Diseases: A Matter of Estrogens, Ceramides, and Sphingosine 1-Phosphate.International journal of molecular sciences · 2022Review
- The Use of ERE-Luc Reporter Mice to Monitor Estrogen Receptor Transcriptional Activity in a Spatio-Temporal Dimension.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Chaigui granule exerts anti-depressant effects by regulating the synthesis of Estradiol and the downstream of CYP19A1-E2-ERKs signaling pathway in CUMS-induced depressed rats.Frontiers in pharmacology · 2022Article
- Advances in Our Understanding of the Mechanism of Action of Drugs (including Traditional Chinese Medicines) for the Intervention and Treatment of Osteoporosis.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postmenopausal hormone therapy (PMHT) is used for the relief of menopausal symptoms, but the dosage has varied greatly throughout its existence. By the end of the 1990s, PMHT was mainly used to prevent chronic diseases such as osteoporosis, coronary heart disease and dementia, and large prevention trials were undertaken in this context. Following the initial negative reports of these trials, use of PMHT dramatically decreased. These reports noted surprisingly increased risks, notably of coronary heart disease, stroke and breast cancer, in people who used PMHT. Nowadays, considering the currently available data, it seems that an important distinction should be made between the treatment of climacteric symptoms in young, generally healthy, postmenopausal women and the prevention of chronic diseases in elderly women. PMHT seems to be beneficial and safe for postmenopausal symptomatic women aged <60 years. Treatments with a high safety profile should be the preferred option, including low-dose PMHT, oestrogen-only therapy in women who have had a hysterectomy, and vaginal oestrogen therapy for women with atrophic vaginitis. Nonandrogenic progestin might have a reduced thrombotic and breast cancer risk, and transdermal oestrogen could have a reduced thrombotic risk. Nevertheless, PMHT should not be used for the prevention of chronic diseases in the elderly (>70 years old) owing to the increased risk of stroke and breast cancer in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.